सत्यमेव जयते

Government of India
Central Drugs Standard Control Organisation(Headquarter)
(Directorate General of Health Services)
FDA Bhavan, ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail: dci@nic.in

File No. BIO/CT/25/000015 Dated 23-06-2025

To
M/s Enzene Biosciences Ltd.,
Plot No. A 22, A/1/2 Chakan Industrial Area,
Phase 2, Khalumbre Chakan, Pune (India) – 410501.

Subject: Application for grant of permission to conduct Phase I Clinical trial titled –" A single center, randomized, double-blind, balanced, pivotal, two period, four-treatment, single-dose, 2-arm, 2-stage, adaptive design, parallel study to assess pharmacokinetic and pharmacodynamic, safety / tolerability and immunogenicity of ENZ210 [Enzene Romiplostim powder for solution for injection (subcutaneous administration)] in comparison with EU approved Nplate in healthy adult human subjects under fasting conditions" vide protocol number CL001-25 Version 00, Dated 04/Feb/2025 – regarding.

Ref.: Your Application No BIO/CT04/FF/2025/47716 dated 04-02-2025.

Sir,

With reference to your Application No. BIO/CT04/FF/2025/47716 dated 04-02-2025, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

(I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;

(II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;

(IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;

(X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;

(XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;

(XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(XVII) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified.

(XVIII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.

(XIX) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of two years from the date of its issue, unless extended by the Central Licencing Authority.

(XX) The firm should submit Clinical study report (CSR) to this office after completion of trial.

(XXI) The firm shall submit the batches that are used for Clinical Trial to National Institute of Biologicals, Noida for testing/analysis.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.06.24 13:48:28 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

File. No. BIO/CT/25/000015

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licencing Authority hereby permits **M/s Enzene Biosciences Ltd., Plot No. A 22, A/1/2 Chakan Industrial Area, Phase 2, Khalumbre Chakan, Pune (India) – 410501** to conduct clinical trial of the new drug or investigational new drug study titled –" A single center, randomized, double-blind, balanced, pivotal, two period, four-treatment, single-dose, 2-arm, 2-stage, adaptive design, parallel study to assess pharmacokinetic and pharmacodynamic, safety / tolerability and immunogenicity of ENZ210 [Enzene Romiplostim powder for solution for injection (subcutaneous administration)] in comparison with EU approved Nplate in healthy adult human subjects under fasting conditions" vide protocol number CL001-25 Version 00, Dated 04/Feb/2025 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date: 23.06.2025

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.06.24 13:49:19 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licensing Authority

Annexure:

Details of new drug or investigational new drug:

<table>
<tr><td>Name of the new drug or investigational new drug</td><td>Romiplostim Injection (r-DNA origin) 250 mcg/vial</td></tr>
<tr><td>Therapeutic class</td><td>Thrombopoietin receptor agonist</td></tr>
<tr><td>Dosage form:</td><td>Lyophilized powder for solution for injection in a single use vial
(to be used as solution for injection for subcutaneous use after reconstitution with sterile water for injection)
Each vial contains 250 mcg of Romiplostim; single use vial</td></tr>
<tr><td>Composition:</td><td>
<table>
<tr><th>Ingredient</th><th>Function</th><th>Qty/Vial (mg)</th></tr>
<tr><td>Romiplostim (r-DNA origin)</td><td>API (Drug Substance)</td><td>0.375 mg</td></tr>
<tr><td>Mannitol (IP, Ph.Eur., BP, USP)</td><td>Tonicity modifier/stabilizer</td><td>30.0 mg</td></tr>
<tr><td>Sucrose (IP, Ph.Eur., BP, JP, NF)</td><td>Tonicity modifier/stabilizer & cryoprotectant</td><td>15.0 mg</td></tr>
<tr><td>L-Histidine (Ph.Eur., USP, JP)</td><td>Buffering agent</td><td>1.2 mg</td></tr>
<tr><td>Polysorbate 20 (IP, BP, EP, JP, NF)</td><td>Surfactant</td><td>0.03 mg</td></tr>
<tr><td>Hydrochloric Acid (IP, Ph.Eur., BP, JP, NF)</td><td>pH adjuster</td><td>q.s. to pH 5.0</td></tr>
</table>
</td></tr>
<tr><td>Indications:</td><td>Romiplostim is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).</td></tr>
</table>

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	Alkem Laboratories Ltd., Bioequivalence Center C-6/1, C-6/2, MIDC Industrial Estate, Taloja, Dist. Raigad – 410 208, Maharashtra, India	Sai Ethics Committee, Sai Hospital, 2nd, 3rd & 4th Floor, Vaibhav Nagar, Katai, Kalyan Shil Phata Road, Dombivali (East) 421201, Maharashtra, India EC Reg. No. ECR/1510/Inst/MH/2021	Dr. Parag Pawar